Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,092 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching antiretrovirals in older patients.
Gianotti N, Castagna A. Gianotti N, et al. Among authors: castagna a. Lancet HIV. 2019 Oct;6(10):e640-e641. doi: 10.1016/S2352-3018(19)30229-2. Lancet HIV. 2019. PMID: 31578950 No abstract available.
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group. Delaugerre C, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451297 Free PMC article. Clinical Trial.
Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F, Marinozzi MC, Sampaolo M, Boeri E, Spagnuolo V, Gianotti N, Castagna A, Paolucci S, Baldanti F, Lazzarin A, Clementi M. Canducci F, et al. Among authors: castagna a. J Antimicrob Chemother. 2010 Mar;65(3):425-33. doi: 10.1093/jac/dkp477. Epub 2010 Jan 7. J Antimicrob Chemother. 2010. PMID: 20056687
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Nozza S, Galli L, Visco F, Soria A, Canducci F, Salpietro S, Gianotti N, Bigoloni A, Torre LD, Tambussi G, Lazzarin A, Castagna A. Nozza S, et al. Among authors: castagna a. AIDS. 2010 Mar 27;24(6):924-8. doi: 10.1097/QAD.0b013e3283372d76. AIDS. 2010. PMID: 20154578
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients; Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, et al. Among authors: castagna a. Lancet. 2010 Jul 31;376(9738):340-5. doi: 10.1016/S0140-6736(10)60932-4. Epub 2010 Jul 15. Lancet. 2010. PMID: 20638118 Free PMC article.
1,092 results